Tulisokibart for Psoriatic Arthritis

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

Recruiting Phase 2 Interventional Study
Psoriatic Arthritis
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
140 (estimated)
Sponsor
Merck Sharp & Dohme LLC · Industry
Who this trial is looking for

This trial is looking for adults with Psoriatic Arthritis who are experiencing active symptoms. Participants will take a study medicine called tulisokibart or a placebo to see if it helps reduce their symptoms better than the placebo.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with Psoriatic Arthritis.
  • I have active plaque psoriasis or a history of it.
  • I have not responded to or cannot tolerate certain arthritis medications.

You may not be able to join if

  • I had arthritis starting before age 17.
  • I have another inflammatory joint disease aside from Psoriatic Arthritis.
  • I have a skin condition other than psoriasis that may affect treatment.
  • I have had cancer within the last 5 years.
  • I have an active infection.
  • I am allergic to tulisokibart or its ingredients.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has a clinical diagnosis of PsA and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening, with symptom onset ≥6 months before Screening. * Has a diagnosis of…
Contacts

Toll Free Number

1-888-577-8839

Trialsites@msd.com

CONTACT